What is the efficacy of the self-expanding transcatheter aortic-valve bioprosthesis (CoreValve) in the treatment of aortic stenosis (AS)?

Updated: May 07, 2019
  • Author: Xiushui (Mike) Ren, MD; Chief Editor: Terrence X O'Brien, MD, MS, FACC  more...
  • Print
Answer

In the ADVANCE study (ArmeD SerVices TrAuma RehabilitatioN OutComE), Linke et al found that implantation of a self-expanding transcatheter aortic valve system (CoreValve System) resulted in a significant improvement in hemodynamics and an increase in the effective aortic valve orifice area in high-risk patients with severe aortic stenosis. [43] Major adverse cardiovascular and cerebrovascular events were 8.0% at 30 days and 21.2% at 12 months; all-cause mortality was 4.5% and 17.9%, respectively; cardiovascular mortality was 3.4% and 11.7%, respectively; and rate of stroke was 3.0% and 4.5%, respectively. [43]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!